Table 3.
Association between the IC biomarkers and the risk of MACCE in unadjusted, minimally adjusted, and final adjusted Cox models
| Unadjusted |
Adjusted for age and HbA1c |
Final models* |
||||
|---|---|---|---|---|---|---|
| HR (95% CI)** | P value | HR (95% CI)** | P value | HR (95% CI)** | P value | |
| DCCT baseline (46 events, n = 518) | ||||||
| AGE-LDL-IC (mg/L) | 1.47 (1.13, 1.93) | 0.005 | 1.42 (1.01, 1.87) | 0.012 | 1.34 (0.99, 1.80) | 0.051 |
| MDA-LDL-IC (mg/L) | 1.30 (1.04, 1.63) | 0.021 | 1.30 (1.03, 1.65) | 0.029 | 1.23 (0.95, 1.60) | 0.109 |
| oxLDL-IC (mg/L) | 1.78 (1.26, 2.51) | 0.001 | 1.72 (1.22, 2.42) | 0.002 | 1.57 (1.10, 2.25) | 0.014 |
| DCCT closeout (43 events, n = 504) | ||||||
| AGE-LDL-IC (mg/L) | 1.37 (1.01, 1.86) | 0.045 | 1.29 (0.95, 1.76) | 0.108 | 1.16 (0.81, 1.66) | 0.419 |
| MDA-LDL-IC (mg/L) | 1.34 (1.05, 1.71) | 0.018 | 1.33 (1.02, 1.73) | 0.035 | 1.23 (0.93, 1.64) | 0.150 |
| oxLDL-IC (mg/L) | 1.87 (1.29, 2.70) | 0.001 | 1.73 (1.19, 2.51) | 0.004 | 1.56 (1.05, 2.31) | 0.028 |
| All measurements (46 events, n = 518) | ||||||
| AGE-LDL-IC (mg/L) | 1.44 (1.08, 1.91) | 0.012 | 1.33 (0.98, 1.79) | 0.064 | 1.21 (0.90, 1.65) | 0.224 |
| MDA-LDL-IC (mg/L) | 1.34 (1.03, 1.75) | 0.029 | 1.28 (0.97, 1.68) | 0.078 | 1.18 (0.90, 1.55) | 0.238 |
| oxLDL-IC (mg/L) | 1.71 (1.20, 2.44) | 0.003 | 1.50 (1.06, 2.13) | 0.022 | 1.34 (0.94, 1.90) | 0.106 |
P values <0.05 are presented in boldface type.
*Adjusted for age, mean HbA1c, cohort, sex, mean SBP, pulse, (log) triglycerides, mean LDL, (log) AER, and duration of T1D.
**Per 1 unit increase in the log-transformed biomarker value. The HR per (for example) a 25% increase in the biomarker (or equivalently, a 1.25-fold change) is given by HR^log(1.25), where “^” denotes “to the power of.” Biomarkers are amount per milligram of apoB contained in the IC, using serum total apoB/L.